Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab vedotin), IgG1
Artikelnummer:
SYB-CHB250
| Artikelname: |
Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab vedotin), IgG1 |
| Artikelnummer: |
SYB-CHB250 |
| Hersteller Artikelnummer: |
CHB250 |
| Alternativnummer: |
SYB-CHB250-100UG,SYB-CHB250-1MG |
| Hersteller: |
Sanyou Bio |
| Kategorie: |
Antikörper |
| Applikation: |
ELISA, FA, FACS, Kinetics |
| Spezies Reaktivität: |
Human |
| Alternative Synonym: |
SGN-LIV1A, anti-LIV-1-vcMMAE, hLIV22 |
| Ladiratuzumab vedotin is an ADC consisting of a LIV-1-directed antibody and Monomethyl auristatin E (MMAE) used for the study of breast cancer. |
| Konzentration: |
1mg/ml |
| Molekulargewicht: |
146.96 kDa |
| Isotyp: |
IgG1 |
| NCBI: |
13433 |
| UniProt: |
Q13433 |
| Puffer: |
25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2 |
| Reinheit: |
>90% |
| Formulierung: |
Lyophilize |
| Target-Kategorie: |
LIV-1 / SLC39A6 |